Publications by authors named "C P Strassburg"
Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures.
Int J Mol Sci
December 2024
This longitudinal study examined how active gastrointestinal (GI) cancer types affect immune responses to SARS-CoV-2, focusing on the ability to neutralize the Omicron variants. Patients with GI cancer ( = 168) were categorized into those with hepatocellular carcinoma, hepatic metastatic GI cancer, non-hepatic metastatic GI cancer, and two control groups of patients with and without underlying liver diseases. Humoral and cellular immune responses were evaluated before and after Omicron antigen exposures.
View Article and Find Full Text PDFArticle Synopsis
- Immunotherapy combinations are the standard treatment for advanced hepatocellular carcinoma (HCC), with growing evidence supporting lenvatinib as a strong first-line option.
- A retrospective study analyzed 412 patients treated with either atezolizumab/bevacizumab (AZ/BV) or lenvatinib (LEN) across 18 European hospitals, revealing that those on AZ/BV experienced longer progression-free survival.
- Despite comparable survival rates between the two treatments overall, AZ/BV posed a higher risk of liver issues in patients with pre-existing liver function impairment, highlighting the need for careful patient monitoring.
Background: Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter study aimed to stratify the risk of HCC development in ACLD.
View Article and Find Full Text PDFLenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with cancer. In this study, we analyze the role of muscle loss in patients with advanced HCC treated with lenvatinib.
View Article and Find Full Text PDFArticle Synopsis
- Primary sclerosing cholangitis (PSC) is a serious liver disease that can cause problems in bile ducts and lead to liver damage.
- This study looked at a special type of PSC where patients have high levels of a protein called IgG4 to see how it affects their health over time.
- They found that about 12.7% of patients had high IgG4 levels, and tracking these levels helps doctors understand different types of PSC better.